/
Psychiatry
Depression
76
Pipeline Programs↗
284
Active Trials↗
83
Companies Involved↗
Depression is a moderately active landscape with 76 programs across 83 companies. The most active players are CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Eleusis Therapeutics. 14 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical44
Phase 217
Phase 314
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
74 of 76 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 76 classified programs, each share of the total. Modality classified for 100% of 76 pipeline programs.
Analysis
Trial Status
1,047
clinical trials
Completed566 · 54%
Recruiting174 · 17%
Terminated86 · 8%
Unknown status74 · 7%
Not yet recruiting61 · 6%
Active, not recruiting44 · 4%
Other42 · 4%
Clinical Trials
Trial Activity
1047 trials
Lumateperone for Late-Life Depression
Recruiting·—·Phase 3·NCT07623135·100 enrolled
Page 1 of 70
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)